{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T14:49:54Z","timestamp":1770475794944,"version":"3.49.0"},"reference-count":14,"publisher":"S. Karger AG","issue":"4","license":[{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatology"],"published-print":{"date-parts":[[2005]]},"abstract":"<i>Background:<\/i> A two-compound product containing calcipotriol and betamethasone dipropionate (Daivobet<sup>\u00ae<\/sup>\/Dovobet<sup>\u00ae<\/sup>) has been evaluated in a large clinical trial programme, providing a wealth of data on the treatment of psoriasis vulgaris. <i>Objective:<\/i> To determine the effectiveness of the two-compound product in patients with mild, moderate and severe psoriasis vulgaris. <i>Methods:<\/i> Data from over 1,534 patients with psoriasis vulgaris who received the two-compound product once daily for at least 4 weeks in four randomised, double-blind studies were pooled. A meta-analysis of the pooled data is presented. Severity of psoriasis at baseline was determined by investigator assessment and Psoriasis Area and Severity Index (PASI) score. <i>Results:<\/i> For patients with severe disease defined by PASI score (PASI baseline \u226717), the mean reduction in PASI after up to 4 weeks of treatment was 71.6% compared with 68.9 and 67.2% for those with moderate (PASI baseline 5.1\u201316.0) and mild disease (PASI baseline \u22645). Corresponding reductions for investigator-assessed severity were 72.6, 69.1 and 68.7%, respectively. <i>Conclusion:<\/i> Although the meta-analysis of the data from these four studies was performed post hoc, we may conclude that the two-compound product provided highly effective treatment of psoriasis, regardless of the category of baseline disease severity.<\/jats:p>","DOI":"10.1159\/000084753","type":"journal-article","created":{"date-parts":[[2005,5,27]],"date-time":"2005-05-27T10:28:02Z","timestamp":1117189682000},"page":"294-299","source":"Crossref","is-referenced-by-count":19,"title":["A Two-Compound Product Containing Calcipotriol and Betamethasone Dipropionate Provides Rapid, Effective Treatment of Psoriasis vulgaris regardless of Baseline Disease Severity"],"prefix":"10.1159","volume":"210","author":[{"given":"P.C.M.","family":"van de Kerkhof","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Wasel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Kragballe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Cambazard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2005,5,30]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1046%2Fj.1365-2133.1997.5541510.x"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001%2Farchderm.101.4.390"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016%2FS0190-9622%2899%2970363-4"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016%2F0190-9622%2893%2970067-4"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016%2F0140-6736%2891%2992157-W"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1046%2Fj.1365-2133.1997.d01-1148.x"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016%2F0190-9622%2892%2970103-M"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1365-2133.2004.05986.x"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1159%2F000066440"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1080%2F00015550252948194"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1046%2Fj.1365-2133.2002.04967.x"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1159%2F000080854"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1067%2Fmjd.2003.130"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1159%2F000071788"}],"container-title":["Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/84753","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/84753","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T03:45:39Z","timestamp":1745466339000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000084753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005]]},"references-count":14,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2005,5,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000084753","archive":["Portico"],"relation":{},"ISSN":["1018-8665","1421-9832"],"issn-type":[{"value":"1018-8665","type":"print"},{"value":"1421-9832","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005]]}}}